Clinical trial · Interventional
Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer
Evaluating a Novel Follow-up Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer Survivors in Wisconsin
NCT05609435CI-TRIAL-00108126completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study tests a novel intervention designed to optimize needed survivorship care for low-risk breast cancer survivors while reducing burdensome care with limited health benefits. This study examines whether the intervention, titled REASSURE, improves survivors' preparedness for survivorship. Up to 110 participants will be on study for up to 18 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| REASSURE | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- REASSURE Follow Up care
- interventionNames
- Other: REASSURE
- type
- NO_INTERVENTION
- label
- Usual Follow Up Care
Primary outcomes (2)
- measure
- Preparing for Life as a (New) Survivor (PLANS) Scale Score: Part 1
- timeFrame
- up to 18 months
- description
- Survivors' preparedness for survivorship will be assessed using Part 1 of the Preparing for Life as a (New) Survivor (PLANS) scale. This is an 11-item survey scored on a 4 point likert scale for a total possible range of score from 11 - 44 where higher scores indicate increased preparedness.
- measure
- Preparing for Life as a (New) Survivor (PLANS) Scale Score: Part 2
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 95 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of stage I, ER and/or PR positive, her2neu negative breast cancer within the last 6-24 monoths * Willing to complete study procedures using email Exclusion Criteria: * Receipt of chemotherapy for the stage I ER and/or PR positive, her2neu negative breast cancer diagnosed within the last 6-24 months * Participants will be excluded if they are unable to read and write in English or if, in the opinion of a treating clinician, have cognitive impairment that would prevent completion of study procedures * Pregnancy, based on patient self-report. If a patient becomes pregnant during the study period, they will be removed from the study at that time. * Diagnosis of a ER and PR negative, her2neu negative breast cancer or a her2neu positive breast cancer within the last 5 years
References
Publications (0)
Data not yet available
No reference posted for this study.